210 related articles for article (PubMed ID: 18254952)
1. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
El Demellawy D; Nasr A; Alowami S
Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
4. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
5. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
[TBL] [Abstract][Full Text] [Related]
6. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
[TBL] [Abstract][Full Text] [Related]
7. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
8. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions.
Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M
Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628
[TBL] [Abstract][Full Text] [Related]
9. Ought to The Changes Within the Immunophenotype of Solid Cell Nests (SCNs) and Follicular Cells in Hashimoto's Thyroiditis be Considered as Premalignant Lesions?
Dung TN; Tuyen NK; Tien TD; Thinh PV; Hassell LA; Van NK; Hung NM; Tra DT; Ben NH; Linh NT
Indian J Endocrinol Metab; 2023; 27(1):37-44. PubMed ID: 37215277
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Borson-Chazot F; Lifante JC; Sturm N; Lavérriere MH; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
[TBL] [Abstract][Full Text] [Related]
13. Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology.
Mokhtari M; Eftekhari M; Tahririan R
J Res Med Sci; 2013 Dec; 18(12):1046-50. PubMed ID: 24523794
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
15. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid.
Prasad PA; Raju K
J Cancer Res Ther; 2022; 18(3):644-649. PubMed ID: 35900535
[TBL] [Abstract][Full Text] [Related]
17. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
[TBL] [Abstract][Full Text] [Related]
18. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
19. CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.
Noroozinia F; Gheibi A; Ilkhanizadeh B; Abbasi A
Acta Endocrinol (Buchar); 2016; 12(4):387-391. PubMed ID: 31149120
[TBL] [Abstract][Full Text] [Related]
20. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.
Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N
Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
